QOL and neurocognitive functions in patients with GBM.

Abstract

2062 Background: The importance of QOL and neurocognitive functions in patients with GBM is meanwhile beyond controversy. We followed newly diagnosed patients with GBM during first and second line therapy by evaluating their QOL and cognitive functions Methods: Consecutive newly diagnosed patients with GBM were included in this study. To assess QOL we used the EORTC QLQ C30 and BN20 questionnaire and the computer based NeuroCog FX for neurocognitive assessments. The first assessment was done at the beginning of radiotherapy and was followed by further 5 evaluations every three months Results: 42 patients underwent radiation therapy with concomitant and adjuvant temozolomide. Non enzyme enhancing antiepileptic drugs (NEIAED) was prescribed for the majority of the patients (71%). Median progression free survival was 9.6 months (2.5-30.9 months). Second line therapies applied were bevacizumab in 11 patients (26%), dose-dense temozolomide in 10 patients (24%) and imatinib in 8 patients. (19%). Neither QOL nor...